Abstract 988P
Background
Liver cancer is a leading cause of cancer-related mortality worldwide. There is a literature gap regarding its burden in the Middle East and North Africa (MENA) region. Therefore, we aimed to investigate the epidemiological trends of primary liver cancer in the MENA region from 1990 to 2019.
Methods
The Global Burden of Disease database was used to extract the age-standardized rates per 100,000 population for prevalence (ASRP), incidence (ASRI), and years lived with disability (YLDs) of primary liver cancer in the MENA region between 1990 and 2019. Data were analyzed to identify regional distribution patterns across different countries and demographic groups using Wilcoxon signed-rank test.
Results
ASRP for liver cancer in the MENA region was significantly higher in 2019 compared to 1990 (median of 4.34 and 5.38 in 1990 and 2019, respectively; P= 0.002). The major causes of primary liver cancer were hepatitis C virus, followed by hepatitis B virus, nonalcoholic steatohepatitis, and alcohol use. In 2019, the highest ASRP was observed in Qatar (24.894; 95% confidence interval (CI): 18.34-33.24) and Egypt (22.575; 95% CI: 16.20-30.90), while Morocco had the lowest one (2.21; 95% CI: 1.68-2.70). On the other hand, no significant increase was observed from 1990 to 2019 for the ASRI (median of 4.26 and 4.49 in 1990 and 2019, respectively, P = 0.498) and YLDs (median of 0.96 and 1.04 in 1990 and 2019, respectively, P = 0.079).
Conclusions
The prevalence of liver cancer shows a rising trend in the MENA region from 1990 to 2019. Adopting regional programs to address the major risk factors should be considered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
978P - Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Presenter: Claudia Fulgenzi
Session: Poster session 18
979P - Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Presenter: Maria Elisa Reig Monzon
Session: Poster session 18
980P - Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
Presenter: Young Mi Hong
Session: Poster session 18
981P - The response of portal vein tumoral thrombosis to moderately hypo-fractionated radiotherapy using intensity modulated radiotherapy
Presenter: Ahmad Abdel-Azeez
Session: Poster session 18
982P - Transarterial chemoembolization with idarubicin versus epirubicin for hepatocellular carcinoma: An interim analysis of a multicentre, randomized controlled phase III trial
Presenter: Zhewei Zhang
Session: Poster session 18
983P - Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study
Presenter: Ming Zhao
Session: Poster session 18
984P - Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: A nationwide cohort study
Presenter: Jo Kook Lee
Session: Poster session 18
987P - Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Presenter: Wonseok Kang
Session: Poster session 18